Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives

被引：45

作者：

Herbreteau, Guillaume ^{[1
]}

Vallee, Audrey ^{[1
]}

Charpentier, Sandrine ^{[1
]}

Normanno, Nicola ^{[2
]}

Hofman, Paul ^{[3
,4
,5
]}

Denis, Marc G. ^{[1
]}

机构：

[1] Nantes Univ Hosp, Dept Biochem, 9 Quai Moncousu, F-44093 Nantes, France

[2] Fdn G Pascale, IRCCS, Ist Nazl Tumori, Cell Biol & Biotherapy Unit, Naples, Italy

[3] Univ Cote Azur, CHU Nice, CNRS 7284, INSERM,Lab Clin & Expt Pathol,U1081, Nice, France

[4] Pasteur Hosp, FHU OncoAge, Nice, France

[5] Pasteur Hosp, Hosp Integrated Biobank BB 0033 00025, Nice, France

来源：

JOURNAL OF THORACIC DISEASE | 2019年 / 11卷

关键词：

Circulating tumor DNA (ctDNA); non-small cell lung cancer (NSCLC); EGFR mutation; ALK translocation; tumor mutation burden (TMB); minimal residual disease (MRD); MOLECULAR TESTING GUIDELINE; T790M RESISTANCE MUTATION; OF-AMERICAN-PATHOLOGISTS; EGFR MUTATION; LIQUID BIOPSY; ACQUIRED-RESISTANCE; ADENOCARCINOMA PATIENTS; CEREBROSPINAL-FLUID; ALK REARRANGEMENT; BRAF MUTATION;

D O I：

10.21037/jtd.2018.12.18

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Major advances in the treatment of non-small cell lung cancer (NSCLC) patients have been obtained during the last decade. Molecular testing of tumor samples is therefore mandatory in routine clinical practice. Tumor DNA is also present as cell-free molecules in blood, which is therefore a very useful and convenient source of tumor DNA. In this review, we discuss pre-analytical and analytical aspects of circulating tumor DNA (ctDNA) analysis. We also describe the use of ctDNA analysis in routine clinical practice, and discuss the potential use of ctDNA monitoring both to identify minimal residual disease and as a potential tool to early identify patients' response to treatment.

引用

页码：S113 / S126

页数：14

共 132 条

[61]

Lindeman NI, 2018, J MOL DIAGN, V20, P129, DOI [10.5858/arpa.2017-0388-CP, 10.1016/j.jtho.2017.12.001, 10.1016/j.jmoldx.2017.11.004]

[62] Quality Control of Next-generation Sequencing-based In vitro Diagnostic Test for Onco-relevant Mutations Using Multiplex Reference Materials in Plasma [J].

Liu, Donglai ;

Zhou, Haiwei ;

Shi, Dawei ;

Shen, Shu ;

Tian, Yabin ;

Wang, Lin ;

Lou, Jiatao ;

Cong, Rong ;

Lu, Juan ;

Zhang, Henghui ;

Zhao, Meiru ;

Zhu, Shida ;

Cao, Zhisheng ;

Jin, Ruilin ;

Wang, Yin ;

Zhang, Xiaoni ;

Yang, Guohua ;

Wang, Youchun ;

Zhang, Chuntao .

JOURNAL OF CANCER, 2018, 9 (09) :1680-1688

[63] Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis [J].

Luo, Jie ;

Shen, Li ;

Zheng, Di .

SCIENTIFIC REPORTS, 2014, 4

[64] Digital PCR Modeling for Maximal Sensitivity, Dynamic Range and Measurement Precision [J].

Majumdar, Nivedita ;

Wessel, Thomas ;

Marks, Jeffrey .

PLOS ONE, 2015, 10 (03)

[65] Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer [J].

McCoach, Caroline E. ;

Le, Anh T. ;

Gowan, Katherine ;

Jones, Kenneth ;

Schubert, Laura ;

Doak, Andrea ;

Estrada-Bernal, Adriana ;

Davies, Kurtis D. ;

Merrick, Daniel T. ;

Bunn, Paul A., Jr. ;

Purcell, W. Tom ;

Dziadziuszko, Rafal ;

Varella-Garcia, Marileila ;

Aisner, Dara L. ;

Camidge, D. Ross ;

Doebele, Robert C. .

CLINICAL CANCER RESEARCH, 2018, 24 (14) :3334-3347

[66] Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer [J].

McCoach, Caroline E. ;

Blakely, Collin M. ;

Banks, Kimberly C. ;

Levy, Benjamin ;

Chue, Ben M. ;

Raymond, Victoria M. ;

Le, Anh T. ;

Lee, Christine E. ;

Diaz, Joseph ;

Waqar, Saiama N. ;

Purcell, William T. ;

Aisner, Dara L. ;

Davies, Kurtis D. ;

Lanman, Richard B. ;

Shaw, Alice T. ;

Doebele, Robert C. .

CLINICAL CANCER RESEARCH, 2018, 24 (12) :2758-2770

[67] ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer [J].

McLeer-Florin, Anne ;

Duruisseaux, Michael ;

Pinsolle, Julian ;

Dubourd, Sylvian ;

Mondet, Julie ;

Houlbracq, Mathilde Phillips ;

Magnat, Nelly ;

Faure, Julien ;

Chatagnon, Amandine ;

de Fraipont, Florence ;

Levra, Matteo Giaj ;

Toffart, Anne-Claire ;

Ferretti, Gilbert ;

Hainaut, Pierre ;

Brarribilla, Elisabeth ;

Moro-Sibilot, Denis ;

Lantuejoul, Sylvie .

LUNG CANCER, 2018, 116 :15-24

[68] Circulating tumor DNA testing in advanced non-small cell lung cancer [J].

Moding, Everett J. ;

Diehn, Maximilian ;

Wakelee, Heather A. .

LUNG CANCER, 2018, 119 :42-47

[69] Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy [J].

Mok, Tony ;

Wu, Yi-Long ;

Lee, Jin Soo ;

Yu, Chong-Jen ;

Sriuranpong, Virote ;

Sandoval-Tan, Jennifer ;

Ladrera, Guia ;

Thongprasert, Sumitra ;

Srimuninnimit, Vichien ;

Liao, Meilin ;

Zhu, Yunzhong ;

Zhou, Caicun ;

Fuerte, Fatima ;

Margono, Benjamin ;

Wen, Wei ;

Tsai, Julie ;

Truman, Matt ;

Klughammer, Barbara ;

Shames, David S. ;

Wu, Lin .

CLINICAL CANCER RESEARCH, 2015, 21 (14) :3196-3203

[70] An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage [J].

Newman, Aaron M. ;

Bratman, Scott V. ;

To, Jacqueline ;

Wynne, Jacob F. ;

Eclov, Neville C. W. ;

Modlin, Leslie A. ;

Liu, Chih Long ;

Neal, Joel W. ;

Wakelee, Heather A. ;

Merritt, Robert E. ;

Shrager, Joseph B. ;

Loo, Billy W., Jr. ;

Alizadeh, Ash A. ;

Diehn, Maximilian .

NATURE MEDICINE, 2014, 20 (05) :552-558

← 2 3 4 5 6 7 8 9 10 11 →